MedMira believes that their rapid flow-through technology (RFT) platform and the methodology behind their rapid diagnostics are among the Company's most valuable assets. As such, MedMira has taken steps to protect these assets with patents in key international markets. Several key patents have been awarded to MedMira and others are pending.
MedMira's intellectual property (IP) estate includes the following:
Patent No. 10/163,675
European Patent Application No. EP1417489
Chinese Patent No. 02819646.5